Navigation Links
Inclinix, Inc. and JSW Life Sciences Announce Formal Strategic Partnership for European Clinical Trial Enrollment
Date:2/21/2012

WILMINGTON, N.C., Feb. 21, 2012 /PRNewswire/ -- Inclinix, Inc. and JSW Life Sciences announce today their formal strategic partnership. This partnership places Inclinix offices in Graz, Austria and expands Inclinix by over one hundred enrollment professionals in Eastern and Western Europe.

"As Inclinix has experienced significant growth over the past year, it has been important for us to identify a European partner that shares our philosophy and performance enrollment model," explains J. Tobin Geatz, Inclinix President and CEO. "We are pleased to have such an excellent partner as JSW Life Sciences to support the enrollment of all of our studies in Europe."

The Inclinix Clinical Enrollment Manager (CEM) programs offer a unique approach to global clinical trial enrollment. CEMs provide in-field enrollment support to investigative sites, focusing on identifying qualified study candidates not only from within the sites' practices, but from the surrounding medical and patient communities as well.

Dr. Manfred Windisch, CEO of JSW Life Sciences, states, "We are excited to combine our clinical expertise and native-language teams with Inclinix's enrollment experience. We look forward to many successful enrollment campaigns through this partnership."

About Inclinix
Inclinix, Inc. specializes in customized Phase I-IV clinical enrollment solutions for pharmaceutical, biotechnology, and medical device organizations. Clients benefit from twelve years of experience in multiple therapeutic areas. Inclinix delivers a customized, site-focused approach to patient recruitment ensuring every available study candidate is identified, qualified and enrolled. By combining an in-field approach with highly targeted patient outreach, Inclinix creates effective enrollment strategies within a performance model. www.inclinix.com

About JSW Life Sciences
JSW Life Sciences is a full service contract research organization. The company performs preclinical as well as clinical research. The preclinical research department focuses on drug development for neurodegenerative diseases. The profound expertise in neuroscience and more than a decade of experience in contract research result in a sustainable advantage for the customer. Validated transgenic & non-transgenic in vivo & in vitro models to address new as well as already established drug targets in neurodegenerative diseases are available. 

The clinical research team ensures an efficient development process from First-in-Man (Phase I) up to and including Post-Marketing-Surveillance-Studies (Phase IV). Our customers benefit from the competent teams at JSW, the use of innovative technology as well as scientific and clinical expertise together with a worldwide network. www.jsw-lifesciences.com   


'/>"/>
SOURCE Inclinix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
Breaking Medicine News(10 mins):